Potential cost-effectiveness of maternal and infant antiretroviral interventions to prevent mother-to-child transmission during breast-feeding

Journal of Acquired Immune Deficiency Syndromes

Volumn 38, Issue 5, 2005, Pages 570-577

  Maclean, Courtney C ^a,b,d   Stringer, Jeffrey S A ^b,c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA   (Zambia)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d NONE   (United States)

Author keywords

Anti HIV agents; Cost benefit analysis; HIV infections; Markov chains; Nevirapine; Vertical disease transmission

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE;

AFRICA; ARTICLE; ARTIFICIAL MILK; BREAST FEEDING; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAUTERINE INFECTION; MAJOR CLINICAL STUDY; NEWBORN; PRIORITY JOURNAL; QUALITY OF LIFE; VERTICAL TRANSMISSION;

ANTI-HIV AGENTS; BREAST FEEDING; COSTS AND COST ANALYSIS; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV INFECTIONS; HIV SEROPREVALENCE; HUMANS; INFANT, NEWBORN; MARKOV CHAINS; NEVIRAPINE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RISK FACTORS; RWANDA; UNITED STATES;

EID: 17144394506     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000142919.51570.88     Document Type: Article

References (31)

1. UNAIDS. Report on the Global HIV/AIDS Epidemie. Geneva: UNAIDS; 2002.
2. Stanecki KA. The AIDS Pandemic in the 21st Century, XIV International Conference on AIDS. Barcelona: USAID/US Census Bureau; 2002.
3. De Cock KM, Fowler MG, Mercier E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA. 2000;283:1175-1182.
4. Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet. 2003;362:859-868.
5. Quay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999;354:795-802.
6. The PMTCT Donations Program. Boehringer Ingelheim and Abbott Laboratories, January 28, 2004. Available at: http://www.pmtctdonations. org/en/welcome/.
7. Fowler MG, Newell ML. Breast-feeding and HIV-1 transmission in resource-limited settings. J Acquir Immune Defic Syndr. 2002;30:230-239.
8. Nicoll A, Newell ML, Peckham C, et al. Infant feeding and HIV-1 infection. AIDS. 2000;14:S57-S74.
9. Dunn DT, Newell ML, Ades AE, et al. Risk of human immunodeficiency virus type 1 transmission through breast-feeding. Lancet. 1992;340:585-588.
10. UNICEF. The State of the World's Children. New York: Oxford University Press; 1997.
11. Macro International and Zambian Central Statistical Office and Ministry of Health. Zambia Demographic and Health Survey, 1996. Calverton, MD: Macro International; 1997.
12. Macro International and U.S. Department of Health. Uganda Demographic and Health Survey, 1996. Calverton, MD: Macro International; 1996.
13. World Health Organization. Effect of breast-feeding on infant and child mortality due to infectious diseases in less developed countries: a pooled analysis. Lancet. 2000;355:451-455.
14. Vyankandondera J. SIMBA: stopping infection from mother-to-child from breast-feeding in Africa: infant prophylaxis. Paper presented at: International AIDS Society Meeting; July 13-16, 2003; Paris.
15. Marseille E, Kahn JG, Mmiro F, et al. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa. Lancet. 1999;354:803-809.
16. World Bank. World Development Report 1993: Investing in Health. New York: Oxford University Press; 1993.
17. Gold MR, Siegel JE, Russell LB, et al. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
18. Stringer JS, Sinkala M, Stout JP, et al. Comparison of two strategies for administering nevirapine to prevent perinatal HIV transmission in high-prevalence, resource-poor settings. J Acquir Immune Defic Syndr. 2003;32:506-513.
19. Rahlenbeck S, Hakizimana C. Deliveries at a district hospital in Rwanda, 1997-2000. Int J Obstet Gynecol. 2002;76:325-328.
20. Shetry AK, Coovadia HM, Maldonado Y, et al. HIVNET 023: a phase I/II study of the safety and plasma concentrations of nevirapine given daily, twice a week or weekly as HIV prophylaxis in breast-feeding infants from birth to 24 weeks in Durban, South Africa and Harare, Zimbabwe. Paper presented at: Third Conference on Global Strategies for the Prevention of HIV Transmission From Mothers to Infants; September 9-13, 2001; Kampala, Uganda.
21. Fowler MG, Mwatha A, Guay L, et al. Effect of nevirapine (NVP) for perinatal HIV prevention appears greatest among women with most advanced disease: subgroup analyses of HIVNET 012. Paper presented at: 9th Conference on Retroviruses and Opportunistic Infections; April 4, 2002; Seattle.
22. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002;29:484-494.
23. Dorenbaum A, Cunningham CK, Gelber RD, et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA. 2002;288:189-198.
24. Nduati R, John G, Mbori-ngacha D, et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA. 2000;283:1167-1174.
25. Spira R, Lepage P, Msellati P, et al. Natural history of human immunodeficiency virus type 1 infection in children: a five-year prospective study in Rwanda. Mother-to-Child HIV-1 Transmission Study Group. Pediatrics. 1999;104:e56.
26. Black RE, Victora CG. Optimal duration of exclusive breast feeding in low income countries. BMJ. 2002;325:1252-1253.
27. Soderlund N, Zwi K, Kinghorn A, et al. Prevention of vertical transmission of HIV: analysis of cost effectiveness of options available in South Africa. BMJ. 1999;318:1650-1656.
28. Stringer EM, Sinkala M, Stringer JS, et al. Prevention of mother-to-child transmission of HIV in Africa: successes and challenges in scaling-up a nevirapine-based program in Lusaka, Zambia. AIDS. 2003;17:1377-1382.
29. Cardinale V. Drug Topics Red Book. Montvale, NJ: Medical Economics Co.; 2000.
30. Fawzi WW, Msamanga G, Hunter D, et al. Randomized trial of vitamin supplements in relation to vertical transmission of HIV-1 in Tanzania. J Acquir Immune Defic Syndr. 2000;23:246-254.
31. UNAIDS Reference Group. Improved methods and assumptions for estimation of the HIV/AIDS epidemic and its impact: recommendations of the UNAIDS Reference Group on Estimates, Modelling, and Projections. AIDS. 2002;16:W1-W14.